The drug and medical device maker Johnson & Johnson kicked off the healthcare earnings season with a better-than-anticipated ...

If you look at the history of the S&P 500 ( ^GSPC -0.40%) index, dividend stocks have played a significant role in ...

Johnson & Johnson on Wednesday reported second quarter results that topped estimates and the company lifted its full-year outlook.

Johnson & Johnson ( JNJ 0.01%) has been a leading healthcare company in the world for decades, and it's one of the most ...

Stay updated on Johnson & Johnson's Q2 earnings as it faces tariff threats, MedTech challenges, and legal risks.

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive ...

Johnson & Johnson’s film, created with Edelman and produced by Brazil’s Czar Sao Paulo, uses the maze as a metaphor for the struggles facing both patients living with depression and their caregivers.

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder.

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.